“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

28 February 2019
Pharma

Visiongain has published a new pharma report Drug Delivery Technologies Market Forecast : Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular, Nasal/Buccal Drug Delivery Technologies, Biologics, Vaccines.

The Drug Delivery Technologies Market is estimated to grow at a CAGR of 7.8% from 2019 to 2029, driven by exciting new technologies and the potential of extending product life by developing new formulations.

Over the last ten years, the global drug delivery technologies market has witnessed a significant increase in the number of drug delivery companies offering innovative technologies to pharmaceutical manufacturers. Drug delivery technology is an important enabling technology for pharmaceutical products. These platforms are often used by pharmaceutical companies for various reasons, which importantly include the extension of product lifecycle.

There are companies developing new technologies to take advantage of the potential for growth that is abundant in this market. This rapidly expanding market provides growth opportunities for developers willing to invest in R&D. This report profiled the selected companies: 3M, Alkermes PLC, Altea Therapeutics Corporation, Antares Pharma Inc., Applied Pharma Research S.A. (APR), Becton, Dickinson & Company and others.

The lead analyst commented that "The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade. This is mainly due to the rising demand from pharmaceutical companies looking to innovate and improve the marketability of their drugs. The potential of extending the patent life of a drug by developing new formulations will act as a driver for the market as it will prompt pharma companies to seek to maximise the return on investment from each marketed drug."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever